Mosapride citrate

/Mosapride citrate
Mosapride citrate 2020-07-11T20:07:04+08:00

Mosapride citrate

Mosapride柠檬酸盐是促胃肠动力化合物,是5HT4激动剂。

中文名:柠檬酸莫沙必利

英文名:Mosapride citrate; TAK-370 citrate; AS-4370 citrate

CAS 号: 112885-42-4

分子式:C₂₇H₃₃ClFN₃O₁₀

分子量:614.02

纯度:>98.0%

DescriptionMosapride citrate is a gastroprokinetic agent that acts as a selective 5HT4 agonist. Target: 5HT4 Mosapride is a gastroprokinetic agent that acts as a selective 5HT4 agonist. The major active metabolite of mosapride, known as M1, additionally acts as a 5HT3 antagonist, which accelerates gastric emptying throughout the whole of the gastrointestinal tract in humans, and is used for the treatment of gastritis, gastro-oesophageal reflux disease, functional dyspepsia and irritable bowel syndrome. It is recommended to be taken on an empty stomach (i.e. at least one hour before food or two hours after food). In addition to its prokinetic properties, mosapride also exerts anti-inflammatory effects on the gastrointestinal tract which may contribute to some of its therapeutic effects. Mosapride also promotes neurogenesis in the gastrointestinal tract which may prove useful in certain bowel disorders. The neurogenesis is due to mosapride's effect on the 5-HT4 receptor where it acts as an agonist.Its common side effects include dry mouth, abdominal pain, dizziness, headache, insomnia, malaise, nausea, diarrhoea and sometimes constipation. Unlike some other prokinetic agents, mosapride has little effect on potassium channels, no effect on hERG transfected cells, and no effect on cardiovascular function that could be detected in tests on humans. Due to the pharmacokinetics of mosapride, it would take 1,000 - 3,000 times the therapeutic dose to elicit cardiovascular effects.
Target5-HT4 Receptor
References[1]. Tack J, et al. Systematic review: cardiovascular safety profile of 5-HT(4) agonists developed for gastrointestinal disorders. Aliment Pharmacol Ther. 2012 Apr;35(7):745-67.

[2]. Curran MP, et al. Mosapride in gastrointestinal disorders. Drugs. 2008;68(7):981-91.

[3]. Odaka T, et al. Serotonin 5- HT4 receptor agonist (mosapride citrate). Nihon Rinsho. 2006 Aug;64(8):1491-4.

电子邮箱
  • enquiry@bestbiochem.com
QQ客服
  • 1652852700 点击这里给我发消息
技术转让
  • 医药化工类技术转让平台